Compare ORIO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORIO | ALLR |
|---|---|---|
| Founded | N/A | 2004 |
| Country | Canada | United States |
| Employees | 188 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0M | 25.6M |
| IPO Year | N/A | 2021 |
| Metric | ORIO | ALLR |
|---|---|---|
| Price | $0.66 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 27.8K | ★ 135.7K |
| Earning Date | 03-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $320,000.00 |
| Revenue This Year | $74.52 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $4.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.77 |
| 52 Week High | $1.40 | $2.35 |
| Indicator | ORIO | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 38.24 | 44.08 |
| Support Level | N/A | $1.01 |
| Resistance Level | $0.96 | $1.29 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 26.71 | 47.95 |
Orion Digital Corp is a financial technology company operating digital platforms across wealth and payments, supported by a consumer lending business in Canada. The Company's Wealth platform, Intelligent Investing, provides long-term investment solutions to the Canadian market. It also operates a consumer lending business in Canada. Its Payments business is conducted through its wholly owned subsidiary, which provides issuer processing, program management, and regulated payment orchestration services across Europe. The Company operates in Canada and Europe, with Canada generating the majority of its revenue.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.